Jade Biosciences, Inc. JBIO
15.14 USD -1.00 (-6.22%)
As ofNov 16, 2026, 2:11 PM EST
14.95 Day range 16.08
10.98 52-week range 28.00
- YTD
- -1.91%
- 1 year
- +41.45%
News
benzinga.com Guggenheim Maintains Buy on Jade Biosciences, Lowers Price Target to $41 Guggenheim analyst Vamil Divan maintains Jade Biosciences (NASDAQ:JBIO) with a Buy and lowers the price target from $47 to $41.
benzinga.com Jade Biosciences Q3 EPS $(0.42) Beats $(0.71) Estimate Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.71) by 40.85 percent. This is a 12.5 percent increase over losses of…
globenewswire.com Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings…benzinga.com BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target BTIG analyst Julian Harrison reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $77 price target.
